MedTrace Logo

Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

NCT02585869 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2020-04-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of gemcabene on HDL-C, LDL-C, TG, and other lipid levels in patients with low HDL-C

Conditions

Interventions

DRUG

Gemcabene 150 mg

Blinded capsules and tablets, 150 mg, once daily, 84 days

DRUG

Gemcabene 300 mg

Blinded capsules and tablets, 300 mg, once daily, 84 days

DRUG

Gemcabene 600 mg

Blinded capsules and tablets, 600 mg, once daily, 84 days

DRUG

Gemcabene 900 mg

Blinded capsules and tablets, 900 mg, once daily, 84 days

DRUG

Placebo

Blinded capsule and tablets, once daily, 84 days

Sponsors & Collaborators

  • NeuroBo Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Primary Completion
2001-06-30
Completion
2001-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02585869 on ClinicalTrials.gov